Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 13/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31387369 | 1.00 | JAK2 (0.36) | JAK2JAK1ATMOPRL1RORC | |
| SCHEMBL26066260 | 0.93 | JAK2 (0.36) | JAK2JAK1OPRL1RORC | |
| SCHEMBL31387422 | 0.93 | JAK2 (0.36) | JAK2JAK1OPRL1RORC | |
| SCHEMBL31387456 | 0.91 | JAK2 (0.35) | JAK2JAK1OPRL1RORC | |
| SCHEMBL30623268 | 0.91 | JAK2 (0.35) | JAK2JAK1OPRL1RORC | |
| SCHEMBL26066279 | 0.91 | JAK2 (0.35) | JAK2JAK1OPRL1RORC | |
| SCHEMBL31387302 | 0.89 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL26059141 | 0.89 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL31387417 | 0.89 | JAK2 (0.35) | JAK2JAK1OPRL1RORC | |
| SCHEMBL26066363 | 0.89 | JAK2 (0.35) | JAK2JAK1OPRL1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171459-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4476227-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171459-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PDXK, PNLIP | JAK2 2939/4885JAK1 2093/4885ATM 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.